Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab

Thrombosis and Haemostasis

Volumn 100, Issue 1, 2008, Pages 151-153

  Hagel, Stefan ^a   Jantsch, Jonathan ^a,b   Budde, Ulrich ^c   Kalden, Joachim R ^a   Eckardt, Kai Uwe ^a   Veelken, Roland ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Aesculabor Hamburg GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; RITUXIMAB; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; IMMUNOMODULATION; KIDNEY FUNCTION; MALE; PHYSICAL EXAMINATION; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT;

ADAM PROTEINS; ADULT; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; BLOOD COMPONENT TRANSFUSION; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; TREATMENT OUTCOME;

EID: 46749124235     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-02-0089     Document Type: Article

References (16)

1. Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood 2005; 106: 11-17.
2. Rizvi MA, Vesely SK, George JN, et al. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000; 40: 896-901.
3. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
4. Tsai HM, Raoufi M, Zhou W, et al. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 2006; 95: 886-892.
5. Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 2005; 12: 359-363.
6. Heidel F, Lipka DB, von Auer C, et al. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007; 97: 228-233.
7. George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006; 21: 49-56.
8. Franchini M, Veneri D, Lippi G, et al. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119-125.
9. Scully M, Cohen H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451-461.
10. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
11. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007; 109: 2815-2822.
12. Cserti CM, Landaw S, Uhl L. Do infections provoke exacerbations and relapses of thrombotic thrombocytopenic purpura? J Clin Apher 2007; 22: 21-25.
13. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
14. McFarland HF. The B cell--old player, new position on the team. N Engl J Med 2008; 358: 664-665.
15. Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 2008; prepub online doi:10.1182/blood- 2007-12-129262.
16. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.